Discordant HER2

Questions discussed in this category

What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?

Initially, presented with cT2N3M0 IDC, ER/PR+, HER2 negative (FISH) on pre-operative biopsies (breast and axilla) → Got neoadjuvant AC-T → L...

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2005-10-20

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

The Lancet. Oncology, 2017-12

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

The New England journal of medicine, 2019-02-14

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

European journal of cancer (Oxford, England : 1990), 2024 Feb 10

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.

Related Topics